Biofrontera Inc. Announces Achievement of Key Milestone in Phase 3 Study of Ameluz®-Photodynamic Therapy (Pdt) in the Treatment of Superficial Basal Cell Carcinoma (Sbcc)
Biofrontera Inc. 宣佈在 Ameluz®-光動力治療 (Pdt) 治療表層基底細胞癌 (Sbcc) 的三期研究中實現關鍵里程碑
Biofrontera Inc. Announces Achievement of Key Milestone in Phase 3 Study of Ameluz®-Photodynamic Therapy (Pdt) in the Treatment of Superficial Basal Cell Carcinoma (Sbcc)
Biofrontera Inc. 宣佈在 Ameluz®-光動力治療 (Pdt) 治療表層基底細胞癌 (Sbcc) 的三期研究中實現關鍵里程碑
使用瀏覽器的分享功能,分享給你的好友吧